PKC inhibitors for the treatment of Bcell lymphoma having chronic active Bcell-receptor signalling

Details for Australian Patent Application No. 2011234644 (hide)

Owner Novartis AG

Inventors Schuler, Walter; Stegmeier, Frank P.; Warmuth, Markus

Agent Davies Collison Cave

Pub. Number AU-A-2011234644

PCT Pub. Number WO2011/120911

Priority 61/425,525 21.12.10 US; 61/319,013 30.03.10 US

Filing date 28 March 2011

Wipo publication date 6 October 2011

International Classifications

A61K 31/00

A61K 31/404

A61K 31/407 - condensed with heterocyclic ring systems, e.g. ketorolac, physostigmine

A61K 31/436

A61K 31/499 - Spiro-condensed pyrazines or piperazines

A61K 31/517 - ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine

A61K 45/06 Medicinal preparations containing active ingredients not provided for in groups

A61P 35/00 Antineoplastic agents

Event Publications

11 October 2012 PCT application entered the National Phase

  PCT publication WO2011/120911 Priority application(s): WO2011/120911

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2011234646-Method for measurement of calcium ions

2011234641-Dye sensitised solar cell